Chenyu Lin, MD

@LeukDocJZ @UNC_SOM @UNC_Lineberger @hopkinskimmel Congrats!

Excited to share that I have been promoted to Professor of Medicine @UNC_SOM @UNC_Lineberger. This milestone could not have been possible w/o the invaluable mentorship from Judy Karp @hopkinskimmel who instilled in me the passion, motivation & drive to improve outcomes in AML.

When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? nejm.org/doi/full/10.10…

Nature Medicine starts an investigation into inconsistencies in a study that found it was better to have immunotherapy in the morning. trib.al/6nK52aA

@Eddie_Cliff @ShafqatInam @BloodPortfolio @KRejeski @RShouval @mike_dickinson1 @TheEBMT @ARampotas @AnnaSureda5 @dgermain21 @PeterMacRes @VJHemOnc @oncodaily @ASH_hematology @NicoGagelmann I understand the rationale for ICI more, what with the theorized impact on DCs. For CAR T, it’s a bit unclear to me why there’d be a circadian effect.

🚨Just out @BloodPortfolio: AusCART consortium looked at time of infusion for 580 pts with LBCL and found no difference in outcomes for pts receiving morning vs afternoon infusions What do you reckon 😜😜 @KRejeski @RShouval? ashpublications.org/blood/article/… #lymsm #CART26

Insightful retrospective analysis published in @BrJHaem from @ChenyuLinMD et al. from @DukeHealth suggests no clear benefit of prophylactic dexamethasone in axi-cel recipients. Following implementation at DUHS, there were no differences in the incidence, timing, duration, or severity of CRS or ICANS, nor in length of hospitalization, ICU utilization, or overall steroid exposure. These findings persisted after multivariable adjustment. Do you give prophy dex at your center? (we rarely do). doi.org/10.1111/bjh.70…

🚨 Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias. I am very pleased with this collaborative effort. Grateful to @MrinalPatnaik for his mentorship. Paper highlights 👇🏽 🧬 PPM1D mutations in clonal hematopoiesis – what really happens after chemo? Multi center study of 337 CH/CCUS patients dissects how #PPM1D and #TP53 mutations shape therapy-related clonal hematopoiesis. 👇 1️⃣ PPM1D is the signature of therapy-related CH •50% had PPM1D-mut/TP53-WT •7% had PPM1D-mut/TP53-mut •These genotypes were highly enriched in therapy-related CH/CCUS (up to 80% of cases). 2️⃣ All PPM1D mutations were truncating exon-6 variants Median VAF only 6% — small clones, but biologically meaningful. 3️⃣ Latency after genotoxic therapy was strikingly short Median time from last chemo/radiation to detection: •PPM1D-mut groups: ~6 months •TP53-mut only: ~11 months •WT/WT: ~24 months → PPM1D clones emerge fast after DNA-damaging therapy. 4️⃣ Strong link with PARP inhibitors & radioligand therapy In therapy-related CH/CCUS: •PARPi exposure: 24–26% in PPM1D-mut vs 0–3% in WT groups •Radioligand therapy: ~25–26% in PPM1D-mut vs near-zero otherwise. 5️⃣ Despite this… PPM1D clones rarely progressed Rates of transformation to MDS/CMML: •PPM1D-mut/TP53-WT: 2% •PPM1D-mut/TP53-mut: 4% •TP53-mut only: 18% •WT/WT: 12% AML transformation occurred only in WT/WT group. 6️⃣ When both PPM1D & TP53 are present, neither always “wins” Among co-mutated patients: •~⅓ #PPM1D-dominant •~⅓ #TP53-dominant •~⅓ co-dominant Therapy-related CH showed more co-dominant competing clones, suggesting chemo creates a “Darwinian battlefield”. 7️⃣ The size of the PPM1D clone matters Using ROC-derived cut-off: •PPM1D VAF ≥13% → independently predicts worse PFS & OS (HR ~2.3 for both). Multiple PPM1D mutations ≠ worse outcome — it’s the clone size, not count. 8️⃣ Clinical message #PPM1D mutations are: •Common after chemo/PARPi/radioligand therapy •Often small, fast-emerging clones •Surprisingly low risk for malignant transformation, even with TP53 — unless the VAF climbs ≥13%. Take-home: PPM1D-mut CH appears to be a therapy-selected, early-emerging, usually indolent precursor state — but rising clone size may signal real danger. doi.org/10.1182/blooda…

Our traditional #COMMAND_consortium meetup at #ASH25 — always a highlight. So proud of this incredible group. @Dr_RoryShallis @Anand_88_Patel @AlexColtoff @ChenyuLinMD @CharlieFoucar #Ehab_Atallah #Eric_Winer we missed @YasminAbaza

@LeukDocJZ @UNC_Lineberger Was there rapping?

@UNC_Lineberger Leukemia Holiday Party! Grateful to work with such a fantastic group of passionate, dedicated, & amazing nurses, advanced practitioners, research coordinators, pharmacists, and clinicians.

High frequency remote digital monitoring detects CRS in #CART and #BiTE ~28 hours faster than standard care. A great honor to present this work on behalf of @DukeCancer and our collaborators at #BlueSparkTechnologies and #Takeda. #ASH25

DCI is participating in a national clinical trial that could reshape the future of CAR T-cell therapy for patients with aggressive lymphoma. duke.is/w/8xat @DukeMedSchool | @DukeHealth | @DukeHMCT

🚨 Exciting news for our leukemia patients! Ziftomenib just received FDA approval for relapsed/refractory NPM1-mutated AML — #leusm @KuraOncology Brief overview of key data: 1/ Phase II trial (KOMET‑001) treated 92 adults with relapsed/refractory NPM1-m AML using once-daily Ziftomenib (600 mg) monotherapy. 2/ PE: rate of CR/CRh 3/ Results CR/CRh rate: 22%, ORR: 33% ; among responders, 61% achieved undetectable MRD 4/ Median DOR: 4.6 months (range 2.8-7.4 m) 5/ Median OS: 6.6 months (95% CI: 3.6-8.6) 6/ Activity was consistent across subgroups including those with prior venetoclax treatment or co-mutations. 7/ Safety profile: Grade ≥3 febrile neutropenia (26 %), anemia (20 %), thrombocytopenia (20 %). Differentiation syndrome occurred in ~25 % (15 % were grade 3; no grade 4/5) doi.org/10.1200/JCO-25…

@LeukDocJZ @VJHemOnc @beatalleukemia @UNC_Lineberger @EuniceWangMD There’s an entire workshop on differentiation syndrome?!

Excited to kick off the 1st Annual International Workshop on Differentiation Syndrome chaired by Eytan Stein and Courtney DiNardo! @VJHemOnc @beatalleukemia @UNC_Lineberger @EuniceWangMD

@mshadman @DrJenniferHuang @fredhutch Great work! 👏👏 Invite us next time!

#ASH25 oral presentation: Dr. @DrJenniferHuang will present the RWE of #CART for #CLL with liso-cel: submit.hematology.org/program/presen… Another great collaboration with our amazing CLL academic community! @fredhutch

Presented at #LIVES2025: In the EVERDAC trial involving patients with shock, results for death at day 28 indicated that management without early arterial catheter insertion was noninferior to early catheter insertion. Full trial results: nej.md/3LmOO0D Editorial: A Less Invasive Approach to Intensive Care nej.md/49b1th5

New Episode of @ASTCT Titans of Transplant, and we’re honored to have CAR-T expert Dr. Sattva Neelapu from @MDAndersonNews We talk about past, present and future of this therapy, lots of wisdom and insight you don’t want to miss it #bmtsm #CARtcell podcasts.apple.com/us/podcast/ast…

#FDA approves a treatment for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. fda.gov/drugs/resource…

Encouraging real world experience (N=9) from @MayoClinic on BCMA-directed CAR T in AL #amyloidosis. ➡️ 89% CRS, 22% G3+ ➡️ 1 IEC-HS, 1 CN palsy ➡️ 75% hematologic CR, 1 VGPR ➡️ 1-yr PFS and OS of 100% ➡️ both cardiac and renal responses seen ashpublications.org/bloodadvances/…

CAR #HEMATOTOX is associated with brexu-cel response, survival, and neutrophil recovery in #ALLsm. Great collaboration with @MSKCancerCenter Yannis Valtis & Jae Park, and #ROCCA consortium @StanfordCancer @LoriMuffly @UChicagoLeuk @RoloffGreg. @DukeCancer ashpublications.org/bloodadvances/…